Production (Stage)
Altamira Therapeutics Ltd.
CYTOF
$0.10
$0.00060.60%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -8.46M | -6.40M | -4.34M | -5.14M | -5.94M |
| Total Depreciation and Amortization | 127.00K | 93.90K | 60.80K | 63.10K | 65.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.19M | 1.42M | 641.80K | 866.90K | 1.09M |
| Change in Net Operating Assets | 28.40K | 230.90K | 433.40K | -1.61M | -3.64M |
| Cash from Operations | -6.11M | -4.66M | -3.20M | -5.82M | -8.43M |
| Capital Expenditure | -103.00K | -51.50K | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 200.00 | 200.00 | 200.00 | 100.00 | -- |
| Other Investing Activities | -12.20K | -5.80K | 600.00 | 400.00 | 200.00 |
| Cash from Investing | -115.40K | -57.40K | 600.00 | 400.00 | 200.00 |
| Total Debt Issued | -- | -- | -- | 1.37M | 2.74M |
| Total Debt Repaid | -137.80K | -105.40K | -73.00K | -122.60K | -172.20K |
| Issuance of Common Stock | 7.37M | 5.01M | 2.64M | 4.33M | 6.03M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -729.40K | -392.90K | -56.40K | -119.10K | -181.80K |
| Cash from Financing | 6.51M | 4.51M | 2.51M | 5.46M | 8.41M |
| Foreign Exchange rate Adjustments | -11.40K | 4.40K | 20.20K | 38.40K | 56.60K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 265.00K | -201.60K | -668.20K | -314.70K | 38.80K |